Lasers in the treatment of nonmelanoma skin cancer

Dermatologic Surgery

Volumn 37, Issue 4, 2011, Pages 409-425

  Choudhary, Sonal ^a,c   Tang, Jennifer ^a   Elsaie, Mohamed L ^a,b   Nouri, Keyvan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER PATIENT; EARLY DIAGNOSIS; ESTHETICS; HUMAN; LOW LEVEL LASER THERAPY; PHOTODYNAMIC THERAPY; PRECANCER; PRIORITY JOURNAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET RADIATION;

HUMANS; LASER THERAPY; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS;

EID: 79954562903     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.01928.x     Document Type: Article

References (117)

1. Silverberg E, Boring CC, Squires TS., Cancer statistics 1990. CA Cancer J Clin 1990; 40: 9-26.
2. Rogers HW, Weinstock MA, Harris AR, et al,. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146: 283-7.
3. Chen JG, Fleischer AB Jr, Smith ED, et al,. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 2001; 27: 1035-8. (Pubitemid 34019722)
4. Ulrich C, Schmook T, Sachse M, et al,. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004; 30: 622-7. (Pubitemid 38525892)
5. Granstein RD., Photoimmunology. In:, Fitzpatrick TB, Eisen AZ, Wolff K, editors. Dermatology in general medicine. New York: McGraw-Hill; 1993. p. 1638-50.
6. Brugarolas J, Chandrasekaran C, Gordon JI., et al,. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552-7.
7. Basset-Seguin N, Moles JP, Mils V, et al,. TP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol 1994; 103: 102S-6S. (Pubitemid 24348783)
8. Bolshakov S, Walker CM, Strom SS, et al,. p53mutations in human aggressive and nonaggressive basal and squamous cellcarcinoma. Clin Cancer Res 2003; 9: 228-34. (Pubitemid 36109738)
9. van Kranen HJ, Westerman A, Berg RJW, et al,. Dose-dependent effects of UVB-induced skin carcinogenesis in hairless p53 knockout mice. Mutat Res 2005; 571: 81-90. (Pubitemid 40313434)
10. Stark LA, Arends MJ, McLaren KM, et al,. Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients. Br J Cancer 1994; 70: 662-7. (Pubitemid 24305593)
11. Jensen P, Hansen S, Moller B, et al,. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-86. (Pubitemid 29072794)
12. Hartevelt MM, Bavinck JN, Kootte AM, et al,. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49: 506-9. (Pubitemid 20110465)
13. Rubel JR, Milford EL, Abdi R., Cutaneous neoplasms in renal transplant patients. Eur J Dermatol 2002; 12: 532-5. (Pubitemid 35440787)
14. Euvrard S, Kanitakis J, Pouteil-Noble C, et al,. Comparative epidemiological study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33: 222-9.
15. Dantal J, Hourmant M, Cantarovich D, et al,. Effect of long-term immunosuppression in kidney graft recipients on cancer incidence: randomized comparison of two cyclosporine regimens. Lancet 1998; 351: 623-8. (Pubitemid 28098444)
16. Gherardini G, Bhatia N, Stal S., Congenital syndromes associated with nonmelanoma skin cancer. Clm Plast Surg 1997; 24: 649-61. (Pubitemid 27446568)
17. Vabres P, Lacombe D, Rabinowitz LG, et al,. The gene for Bazex-Dupré-Christol syndrome. J Invest Dermatol 1995; 105: 87-91.
18. Vennos EM, Collins M, James WD., Rothmund-Thomson syndrome: a review of the world literature. J Am Acad Dermatol 1992; 27: 750-62.
19. Nguyen T, Ho D., Nonmelanoma skin cancer. Curr Treat Options Oncol 2002; 3: 193-203.
20. Shriner DL, McCoy DK, Goldberg DJ, Wagner RF Jr, Mohs micrographic surgery. J Am Acad Dermatol 1998; 39: 79-97. (Pubitemid 28332311)
21. Thissen MR, Neumann MH, Schouten LJ., A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-83. (Pubitemid 29493277)
22. Neville JA, Welch E, Leffell DJ., Management of nonmelanoma skin cancer 2007. Nature 2007; 4: 462-9. (Pubitemid 47393802)
23. Rowe DE, Carroll RJ, Day CL Jr, Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. J Am Acad Dermatol 1992; 26: 976-90.
24. Voss N, Kim-Sing C., Radiotherapy in the treatment of dermatologic malignancies. Dermatol Clin 1998; 16: 313-20. (Pubitemid 28205027)
25. Aldara (imiquimod) cream, 5% [package insert]. St Paul, MN: 3M Pharmaceuticals;2004.
26. Love WE, Bernhard JD, Bordeaux JS., Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145: 1431-8.
27. Murphy ME, Brodland DG, Zitelli JA., Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series. Dermatol Surg 2008; 34: 1258-63.
28. Chakrabarty A, Geisse J., Medical therapies for non-melanoma skin cancer. Clin Dermatol 2004; 22: 183-8. (Pubitemid 38950744)
29. Dillaha CJ, Jansen GT, Honeycutt WM, Bradford AC., Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 1983; 119: 774-83. (Pubitemid 13051157)
30. Alpsoy E, Yilmaz E, Basaran E, Yazar S., Comparison of the effects of intralesional interferon alfa-2a, 2b, and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol 1996; 23: 394-7.
31. Peris K, Fargnoli MC, Chimenti S., Preliminary observations on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med 1999; 341: 1767-8.
32. Bianchi L, Orlandi A, Campione E, et al,. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 2004; 151: 148-56. (Pubitemid 39061292)
33. Good LM, Miller MD, High WA., Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol 2009; 64: 413-22.
34. Cornell RC, Greenway HT, Tucker SB, et al,. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700. (Pubitemid 20336398)
35. Steinquist B, Wennberg AM, Gisslén H, Larkö O., Treatment of aggressive basal cell carcinoma with intralesional interferon: an evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 1992; 27: 65-9.
36. Gordon KB, Garden JM, Robinson JK., Bowen's disease of the distal digit: outcome of treatment with carbon dioxide laser vaporization. Dermatol Surg 1996; 22: 723-8. (Pubitemid 26292012)
37. Adams EL, Price NM., Treatment of basal-cell carcinomas with a carbon-dioxide laser. J Dermatol Surg Oncol 1979; 5: 803-6. (Pubitemid 10249065)
38. Wheeland RG, Bailin PL, Ratz JL, Roenigk RK., Carbon dioxide laser vaporization and curettage in the treatment of large or multiple superficial basal cell carcinomas. J Dermatol Surg Oncol 1987; 13: 119-25. (Pubitemid 17018040)
39. Olbricht SM, Stern RS, Tang SV, et al,. Complications of cutaneous laser surgery: a survey. Arch Dermatol 1987; 123: 345-9. (Pubitemid 17024672)
40. Kauvar A, Waldorf H, Geronemus R., A histopathological comparison of "char-free" carbon dioxide lasers. Dermatol Surg 1996; 22: 343-8.
41. Trelles M, David L, Rigau J., Penetration depth of ultrapulse carbon dioxide laser in human skin. Dermatol Surg 1996; 22: 863-5. (Pubitemid 26399406)
42. Cotton J, Hood A, Gonin R, et al,. Histologic evaluation of preauricular and postauricular human skin after high-energy, short-pulse carbon dioxide laser. Arch Dermatol 1996; 132: 425-8. (Pubitemid 26113393)
43. Waldorf HA, Kauvar A, Geronemus R., Skin resurfacing of fine to deep rhytides using a char-free carbon dioxide laser in 47 patients. Dermatol Surg 1995; 21: 940-6.
44. 2 laser: observations on 100 patients. Dermatol Surg 1995; 21: 1025-9. (Pubitemid 26013044)
45. 2 laser resurfacing on photoaged facial skin. Arch Dermatol 1996; 132: 395-402. (Pubitemid 26113388)
46. Bernstein LJ, Kauvar A, Grossman M, Geronemus R., The short- and long-term effects of carbon dioxide laser resurfacing. Dermatol Surg 1997; 23: 519-25. (Pubitemid 27305248)
47. Gloster HM Jr, Roenigk RK., Carbon dioxide laser for the treatment of cutaneous lesions. Clin Dermatol 1995; 13: 25-33.
48. Fitzpatrick RE, Goldman MP., Advances in carbon dioxide laser surgery. Clin Dermatol 1995; 13: 35-47.
49. 2 laser: a case report. Update Dermatol Laser Surg 1993; 3: 2.
50. Rowe DE, Carroll RJ, Day CL., Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-28. (Pubitemid 19085793)
51. Horlock N, Grobbelaar AO, Gault DT., Can the carbon dioxide laser completely ablate basal cell carcinomas? A histological study. Br J Plast Surg 2000; 53: 286-93. (Pubitemid 30386857)
52. Kilmer S, Chotzen V., Ultrapulse laser treatment of basal cell carcinomas. In: Program and abstracts of the meeting of the American Society of Laser Medicine and Surgery; April 16-24, 1996; Orlando, FL. p. 36, abstract 202.
53. 2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 1999; 25: 729-32. (Pubitemid 29436937)
54. Campolmi P, Brazzini B, Urso C, et al,. Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination. Dermatol Surg 2002; 28: 909-11; discussion 912.
55. Humphreys TR, Malhotra R, Scharf MJ, et al,. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high-energy pulsed carbon dioxide laser. Arch Dermatol 1998; 134: 1247-52. (Pubitemid 28513261)
56. Wollina U, Konrad H, Karamfilov T., Treatment of common warts and actinic keratoses by Er: YAG laser. J Cutan Laser Ther 2001; 3: 63-6. (Pubitemid 34112670)
57. Jiang SB, Levine VJ, Nehal KS, et al,. Er:YAG laser for the treatment of actinic keratoses. Dermatol Surg 2000; 26: 437-40. (Pubitemid 30305322)
58. Karsai S, Czarnecka A, Jünger M, Raulin C., Ablative fractional lasers (CO(2) and Er:YAG): a randomized controlled double-blind split-face trial of the treatment of peri-orbital rhytides. Lasers Surg Med 2010; 42: 160-7.
59. Newman JB, Lord JL, Ash K, McDaniel DH., Variable pulse erbium:YAG laser skin resurfacing of perioral rhytides and side-by-side comparison with carbon dioxide laser. Lasers Surg Med 2000; 26: 208-14. (Pubitemid 30118381)
60. Iyer S, Friedli A, Bowes L, et al,. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med 2004; 34: 114-9. (Pubitemid 38326354)
61. Winton GB, Salasche SJ., Dermabrasion of the scalp as a treatment for actinic damage. J Am Acad Dermatol 1986; 14: 661-8. (Pubitemid 16167354)
62. 2 laser, trichloacetic acid, Baker-Gordon phenol, and dermabrasion: a comparative clinical and histologic study of cutaneous resurfacing in a porcine model. Arch Dermatol 1996; 132: 469-71. (Pubitemid 26113403)
63. Cotton J, Hood AF, Gonin R, et al,. Histologic evaluation of preauricular and postauricular human skin after high-energy, short-pulsed carbon dioxide laser. Arch Dermatol 1996; 132: 425-8. (Pubitemid 26113393)
64. 2 laser on photoaged skin. Plast Reconstr Surg 1997; 99: 2036-50.
65. 2 laser skin resurfacing: a comparison of scanned and pulsed systems. J Am Acad Dermatol 1997; 37: 709-18. (Pubitemid 27500313)
66. Katugampola GA, Lanigan SW., Five years' experience of treating port wine stains with the flashlamp-pumped pulsed dye laser. Br J Dermatol 1997; 137: 750-4. (Pubitemid 27496192)
67. Waldorf HA, Alster TS, McMillan K., Effect of dynamic cooling on 585 nm pulsed dye laser treatment of port-wine stain birthmarks. Dermatol Surg 1997; 23: 657-62. (Pubitemid 27329828)
68. Greve B, Raulin C., Prospective study of port wine stain treatment with dye laser: comparison of two wavelengths (585 nm vs. 595 nm) and two pulse durations (0.5 milliseconds vs. 20 milliseconds). Lasers Surg Med 2004; 34: 168-73. (Pubitemid 38326362)
69. Jasim ZF, Woo WK, Handley JM., Long-pulsed (6 ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg 2004; 31: 37-40. (Pubitemid 38174026)
70. Neville JA, Welch E, Leffell DJ., Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007; 4: 462-9. (Pubitemid 47393802)
71. Chen GS, Yu HS, Lan CC, et al,. CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol 2006; 154: 910-8.
72. Grunt TW, Lametschwandtner A, Staindl O., The vascular pattern of basal cell tumors: light microscopy and scanning electron microscopic study on vascular corrosion casts. Microvasc Res 1985; 29: 371-86. (Pubitemid 16158231)
73. Pikkula BM, Chang DW, Nelson JS, Anvari B., Comparison of 585 and 595 nm laser-induced vascular response of normal in vivo human skin. Lasers Surg Med 2005; 36: 117-23. (Pubitemid 40315483)
74. Zeitels SM, Franco RA Jr, Dailey SH, et al,. Office-based treatment of glottal dysplasia and papillomatosis with the 585-nm pulsed dye laser and local anesthesia. Ann Otol Rhinol Laryngol 2004; 113: 265-76. (Pubitemid 38500470)
75. Britton JE, Goulden V, Stables G, et al,. Investigation of the use of the pulsed dye laser in the treatment of Bowen's disease using 5-aminolaevulinic acid phototherapy. Br J Dermatol 2005; 153: 780-4. (Pubitemid 41415905)
76. Allison KP, Kiernan MN, Waters RA, Clement RM., Pulsed dye laser treatment of superficial basal cell carcinoma: realistic or not? Lasers Med Sci 2003; 18: 125-6. (Pubitemid 37127704)
77. Campolmi P, Mavilia L, Bonan P, et al,. 595 nm pulsed dye laser for the treatment of superficial basal cell carcinoma. Lasers Med Sci 2005; 20: 147-8. (Pubitemid 41797986)
78. Campolmi P, Troiano M, Bonan P, et al,. Vascular based non conventional dye laser treatment for basal cell carcinoma. Dermatol Ther 2008; 21: 402-5.
79. Shah SM, Konnikov N, Duncan LM, Tannous ZS., The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers Surg Med 2009; 41: 417-22.
80. Moskalik K, Kozlov A, Demin E, Boiko E., The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers. Photomed Laser Surg 2009; 27: 345-9.
81. Wolf P, Rieger E, Kerl H., Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? J Am Acad Dermatol 1993; 28: 17-21. (Pubitemid 23019558)
82. Jeffes EW, McCullough JL, Weinstein GD, et al,. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol 1997; 133: 727-32. (Pubitemid 27263706)
83. Cairnduff F, Stringer MR, Hudson EJ, et al,. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994; 69: 605-8. (Pubitemid 24076490)
84. Morton CA, Whitehurst C, Moseley H, et al,. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996; 135: 766-71. (Pubitemid 26375895)
85. Svanberg K, Andersson T, Killander D, et al,. Photodynamic therapy of non-melanoma malignant tumours of the skin using topicalÎ-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-51. (Pubitemid 24218666)
86. Calzavara-Pinton PG., Repetitive photodynamic therapy with topical delta-aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B Biol 1995; 29: 53-7.
87. Fritsch C, Goerz G, Ruzicka T., Photodynamic therapy in dermatology. Arch Dermatol 1998; 134: 207-14. (Pubitemid 28119672)
88. Peng Q, Warloe T, Berg K, et al,. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-308. (Pubitemid 27251011)
89. Alster TS, Tanzi EL, Welsh EC., Photorejuvenation of facial skin with topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a split-face comparison study. J Drugs Dermatol 2005; 4: 35-8.
90. Gold MH, Bradshaw VL, Boring MM, et al,. Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. Dermatol Surg 2006; 32: 795-801. (Pubitemid 43847114)
91. Kennedy JC, Pottier RH, Pross DC., Photodynamic therapy with endogenous protoporphyrin IX. Basic principles and present clinical experience. J Photochem Photobiol B Biol 1990; 6: 143-8.
92. Stables GI, Stringer MR, Robinson DJ, Ash DV., Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy. Br J Dermatol 1997; 136: 957-60. (Pubitemid 27283535)
93. Calzavara-Pinton PG, Venturini M, Sala R., Photodynamic therapy: update 2006. Part 1: Photochemistry and photobiology. J Eur Acad Dermatol Venereol 2007; 21: 293-302.
94. Brancaleon L., Lasers and non-laser light sources for PDT. Lasers Med Sci 2002; 17: 173-86.
95. Brancaleon L, Moseley H., Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci 2002; 17: 173-86.
96. Curnow A, Haller JC, Bown SG., Oxygen monitoring during 5-aminolaevulinic acid induced photodynamic therapy in normal rat colon. Comparison of continuous and fractionated light regimes. J Photochem Photobiol 2000; 58: 149-55. (Pubitemid 32117880)
97. Kawauchi S, Morimoto Y, Sato S, et al,. Differences between cytotoxicity in photodynamic therapy using a pulsed laser and a continuous wave laser: study of oxygen consumption and photobleaching. Lasers Med Sci 2004; 18: 179-83. (Pubitemid 38660651)
98. Miyamoto Y, Umebayashi Y, Nishisaka T., Comparison of phototoxicity mechanism between pulsed and continuous wave irradiation in photodynamic therapy. J Photochem Photobiol 1999; 53: 53-9. (Pubitemid 30047586)
99. Strasswimmer J, Grande DJ., Do pulsed lasers produce an effective photodynamic therapy response? Lasers Surg Med 2006; 38: 22-5. (Pubitemid 43238081)
100. Souza CS, Felicio LB, Ferreira J, et al,. Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for non-melanoma skin cancer. Photodiagnosis Photodyn Ther 2009; 6: 207-13.
101. Wang I, Bendsoe N, Klinteberg CA, et al,. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-40. (Pubitemid 32374789)
102. Karrer S, Baumler W, Abels C, et al,. Long-pulse dye laser for photodynamic therapy: investigations in vitro and in vivo. Lasers Surg Med 1999; 25: 51-9. (Pubitemid 29379091)
103. Fang JY, Lee WR, Shen SC, et al,. Enhancement of topical 5-aminolaevulinic acid delivery by erbium:YAG laser and microdermabrasion: a comparison with iontophoresis and electroporation. Br J Dermatol 2004; 151: 132-40.
104. Wang KH, Fang JY, Hu CH, Lee WR., Erbium:YAG laser pretreatment accelerates the response of Bowen's disease treated by topical 5-fluorouracil. Dermatol Surg 2004; 30: 441-5.
105. Smucler R, Vlk M., Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med 2008; 40: 153-8. (Pubitemid 351354772)
106. Whitaker IS, Shokrollahi K, James W, et al,. Combined CO(2) laser with photodynamic therapy for the treatment of nodular basal cell carcinomas. Ann Plast Surg 2007; 59: 484-8. (Pubitemid 351339070)
107. Thissen MR, Schroeter CA, Neumann HA., Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000; 142: 338-9. (Pubitemid 30117707)
108. de Blois AW, Grouls RJ, Ackerman EW, Wijdeven WJ., Development of a stable solution of 5-aminolaevulinic acid for intracutaneous injection in photodynamic therapy. Lasers Med Sci 2002; 17: 208-15.
109. Tierney EP, Hanke CW., Cost effectiveness of Mohs micrographic surgery: review of the literature. J Drugs Dermatol 2009; 8: 914-22.
110. Bath-Hextall FJ, Perkins W, Bong J, Williams HC., Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007:CD003412.
111. Mosterd K, Krekels GA, Nieman FH, et al,. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 2008; 9: 1149-56.
112. Lopez RFV, Bentley MVLB, Delgado-Charro MB, Guy RH., Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH. Pharm Res 2001; 18: 311-5. (Pubitemid 32595818)
113. Charoo NA, Rahman Z, Repka MA, Murthy SN., Electroporation: An avenue for transdermal drug delivery. Curr Drug Delivery 2010; 7: 125-36.
114. Gerritsen MJ, Smits T, Kleinpenning MM, et al,. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009; 218: 193-202.
115. Christensen E, Skogvoll E, Viset T, et al,. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol 2009; 23: 58-66.
116. Mikolajewska P, Juzeniene A, Moan J., Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy. Transl Res 2008; 152: 128-33.
117. Curnow A, Pye A., Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors. J Environ Pathol Toxicol Oncol 2007; 26: 89-103. (Pubitemid 47295561)